Table 2 Baseline differences by group... | American Society of Hematology

Table 2

Baseline differences by group

Pretransplantation variable	Plateau	Refractory	Relapse on therapy	Relapsed-refractory*	P
Serum M-protein spike, g/L	5	15	17	16	< .001
Plasma cells, %	6	23	20	22	< .001
β₂-microglobulin, mg/L	2.19	3.42	2.71	2.90	< .001
Abnormal cytogenetics at SCT, %	10	21	36	28	< .001
Labeling index	0	0.4	1.2	1.0	< .001
Age, y	59	58	61	60	.92
Creatinine, μM	79	88	79	88	.58
Period from diagnosis to SCT, mo	6.2	6.1	10.9	6.8	< .02

Pretransplantation variable	Plateau	Refractory	Relapse on therapy	Relapsed-refractory*	P
Serum M-protein spike, g/L	5	15	17	16	< .001
Plasma cells, %	6	23	20	22	< .001
β₂-microglobulin, mg/L	2.19	3.42	2.71	2.90	< .001
Abnormal cytogenetics at SCT, %	10	21	36	28	< .001
Labeling index	0	0.4	1.2	1.0	< .001
Age, y	59	58	61	60	.92
Creatinine, μM	79	88	79	88	.58
Period from diagnosis to SCT, mo	6.2	6.1	10.9	6.8	< .02

SCT indicates stem cell transplantation.

Aggregates relapse on therapy and primary refractory into a single group.